share_log

6-K: Rene Haas and Birgit Conix Have Been Appointed as Non-Executive Directors

6-K: Rene Haas and Birgit Conix Have Been Appointed as Non-Executive Directors

6-K:Rene Haas 和 Birgit Conix 被任命爲非執行董事
美股SEC公告 ·  2024/12/16 15:08

牛牛AI助理已提取核心訊息

AstraZeneca announced the appointment of two new Non-Executive Directors: Rene Haas, CEO of Arm, and Birgit Conix, CFO of Sonova, effective January 1, 2025, and February 1, 2025, respectively. Birgit Conix will join the Audit Committee upon her appointment to the Board.Rene Haas brings extensive technology expertise, particularly in data science, computing, and AI from his leadership in the semiconductor industry. He led Arm's successful IPO in September 2023 and previously served as President of Arm's IP Product Groups. His experience includes executive roles at NVIDIA and other tech companies.Birgit Conix contributes significant financial acumen from her CFO roles at Sonova and TUI, along with 15 years of pharmaceutical industry experience. She currently serves on ASML's Supervisory Board as ESG Committee Chair. These appointments are part of AstraZeneca's board refreshment strategy, anticipating the departure of four current Non-Executive Directors in coming years.
AstraZeneca announced the appointment of two new Non-Executive Directors: Rene Haas, CEO of Arm, and Birgit Conix, CFO of Sonova, effective January 1, 2025, and February 1, 2025, respectively. Birgit Conix will join the Audit Committee upon her appointment to the Board.Rene Haas brings extensive technology expertise, particularly in data science, computing, and AI from his leadership in the semiconductor industry. He led Arm's successful IPO in September 2023 and previously served as President of Arm's IP Product Groups. His experience includes executive roles at NVIDIA and other tech companies.Birgit Conix contributes significant financial acumen from her CFO roles at Sonova and TUI, along with 15 years of pharmaceutical industry experience. She currently serves on ASML's Supervisory Board as ESG Committee Chair. These appointments are part of AstraZeneca's board refreshment strategy, anticipating the departure of four current Non-Executive Directors in coming years.
阿斯利康宣佈任命兩位新的非執行董事:Arm的首席執行官Rene Haas和Sonova的財務長Birgit Conix,分別於2025年1月1日和2025年2月1日生效。Birgit Conix在被任命至董事會後將加入審計委員會。Rene Haas在半導體行業的領導中帶來了豐富的科技專長,特別是在數據科學、計算和人工智能方面。他在2023年9月成功領導了Arm的首次公開募股 anteriormente,並擔任過Arm的IP產品組總裁。他的經歷包括在英偉達及其他科技公司的高管職位。Birgit Conix在Sonova和TUI的財務長職位中積累了豐富的財務洞察,以及15年的藥品行業經驗。她目前擔任ASML監事會的ESG委員會主席。這些任命是阿斯利康董事會更新策略的一部分,預計在未來幾年將有四位現任非執行董事離職。
阿斯利康宣佈任命兩位新的非執行董事:Arm的首席執行官Rene Haas和Sonova的財務長Birgit Conix,分別於2025年1月1日和2025年2月1日生效。Birgit Conix在被任命至董事會後將加入審計委員會。Rene Haas在半導體行業的領導中帶來了豐富的科技專長,特別是在數據科學、計算和人工智能方面。他在2023年9月成功領導了Arm的首次公開募股 anteriormente,並擔任過Arm的IP產品組總裁。他的經歷包括在英偉達及其他科技公司的高管職位。Birgit Conix在Sonova和TUI的財務長職位中積累了豐富的財務洞察,以及15年的藥品行業經驗。她目前擔任ASML監事會的ESG委員會主席。這些任命是阿斯利康董事會更新策略的一部分,預計在未來幾年將有四位現任非執行董事離職。

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。

    聲明

    本頁的譯文內容由軟件翻譯。富途將竭力但卻不能保證翻譯內容之準確和可靠,亦不會承擔因任何不準確或遺漏而引起的任何損失或損害。